<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011045</url>
  </required_header>
  <id_info>
    <org_study_id>PA18-0791</org_study_id>
    <secondary_id>NCI-2021-08429</secondary_id>
    <secondary_id>PA18-0791</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT05011045</nct_id>
  </id_info>
  <brief_title>Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies</brief_title>
  <official_title>Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses neurocognitive outcomes after receiving radiation therapy to the brain&#xD;
      (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies).&#xD;
      This may help researchers learn more about the effects of whole brain radiation therapy on&#xD;
      memory and thinking in patients with blood cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Record patients' cognitive outcomes after whole-brain radiation therapy (WBRT) for&#xD;
      hematologic malignancies using standard-of-care neurocognitive function testing.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess patients' quality-of-life after WBRT for hematologic malignancies, based on a&#xD;
      validated questionnaire.&#xD;
&#xD;
      II. Explore magnetic resonance imaging (MRI) changes in the brain after WBRT for hematologic&#xD;
      malignancies, based on standard-of-care imaging studies.&#xD;
&#xD;
      III. Study the role of Memantine in patients' cognitive outcomes during and after WBRT for&#xD;
      hematologic malignancies, based on standard-of-care use, utilizing standard-of-care&#xD;
      neurocognitive function testing.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo neurocognitive function assessments, complete questionnaires over 8-10&#xD;
      minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of&#xD;
      WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive outcomes</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Neurocognitive failure will be defined as the first cognitive failure on 2 or more of the following tests: the Hopkins Verbal Learning Test Revised Total Recall, Delayed Recall and Delayed Recognition; the Controlled Oral Word Association; and the Trail Making Test Part A or B. The rate of neurocognitive failure and its 95% confidence interval (CI) will be calculated. The cumulative incidence approach may be used to estimate the median time to neurocognitive failure to account for the competing risk of death. May use the Aalen-Johansen estimator of the cumulative incidence function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Assessed using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30/Brain Neoplasm 20. The rates of improvement and worsening will be calculated. The rate of deterioration will be calculated. Also, Wilcoxon signed rank test or paired t-test will be used to compare the scores between baseline and after radiation at 2 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging (MRI) changes</measure>
    <time_frame>Baseline up to 5 years</time_frame>
    <description>Will explore radiographic changes on standard-of-care MRI scans that are suggestive of radiation toxicity. Radiographic changes will be considered in the context of radiation treatment plans. Correlation of radiographic changes with radiation dose will be performed for hypothesis generation. Spearman correlation coefficient may be used to assess the correlation between radiographic changes and radiation dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of medications indicated to improve memory and cognitive function</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Neurocognitive outcomes at different time points will be summarized using descriptive statistics. Changes overtime on neurocognitive outcomes may be analyzed using generalized linear models for the repeated measures. May compare the neurocognitive outcomes of the patients to a similar cohort of patients that were not treated with Memantine or other medications indicated to improve memory and cognitive function (example the RT arm of RTOG 1114). Will amend the protocol to include the details on which cohort of patients to be compared to, variables to be used for matching the two patient cohorts, and method to be used for matching once decided to proceed with the comparison.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Secondary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>Observational (neurocognitive assessment, questionnaires, MRI)</arm_group_label>
    <description>Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>Observational (neurocognitive assessment, questionnaires, MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurocognitive Assessment</intervention_name>
    <description>Undergo neurocognitive function assessment</description>
    <arm_group_label>Observational (neurocognitive assessment, questionnaires, MRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (neurocognitive assessment, questionnaires, MRI)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (neurocognitive assessment, questionnaires, MRI)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with radiation therapy to the brain for a hematologic malignancies&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Treatment with radiation therapy to the brain for a hematologic malignancy (ex.&#xD;
             primary central nervous system lymphoma [PCNSL], secondary central nervous system&#xD;
             lymphoma [SCNSL], leukemia, myeloma)&#xD;
&#xD;
          -  Proficient and capable of completing tests in English&#xD;
&#xD;
          -  Patients with claustrophobia are eligible if the claustrophobia is managed with&#xD;
             medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bouthaina S Dabaja</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dustin M. Silk</last_name>
      <phone>713-563-3090</phone>
      <email>dmsilk@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Bouthaina S. Dabaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

